Baseline data for patients with Truven commercial claims (720.0 cohort).
| Characteristics | Total AS Study Population, n = 11,945 | With Chronic Opioid Use, n = 2812 | Without Chronic Opioid Use, n = 9133 | p (chronic opioid use vs not) |
|---|---|---|---|---|
| Age, yrs | < 0.0001 | |||
| Mean (SD) | 46 (11.6) | 48 (10.3) | 45 (11.9) | |
| 18–24 | 738 (6.2) | 74 (2.6) | 664 (7.3) | |
| 25–34 | 1575 (13.2) | 301 (10.7) | 1274 (13.9) | |
| 35–44 | 2798 (23.4) | 610 (21.7) | 2188 (24.0) | |
| 45–54 | 3599 (30.1) | 961 (34.2) | 2638 (28.9) | |
| ≥ 55 | 3235 (27.1) | 866 (30.8) | 2369 (25.9) | |
| Sex | < 0.0001 | |||
| Female | 5462 (45.7) | 1401 (49.8) | 4061 (44.5) | |
| Male | 6483 (54.3) | 1411 (50.2) | 5072 (55.5) | |
| Rheumatologist as provider on index claim | < 0.0001 | |||
| Yes | 6958 (58.3) | 1468 (52.2) | 5490 (60.1) | |
| Comorbidities | ||||
| Depression | 1853 (15.5) | 715 (25.4) | 1138 (12.5) | < 0.0001 |
| Anxiety | 1653 (13.8) | 587 (20.9) | 1066 (11.7) | < 0.0001 |
| RA | 946 (7.9) | 349 (12.4) | 597 (6.5) | < 0.0001 |
| PsA | 477 (4.0) | 143 (5.1) | 334 (3.7) | 0.0007 |
| Psoriasis | 381 (3.2) | 93 (3.3) | 288 (3.2) | 0.6848 |
| IBD | 675 (5.7) | 201 (7.1) | 474 (5.2) | < 0.0001 |
| Opioid dependence or abuse | 180 (1.5) | 133 (4.7) | 47 (0.5) | < 0.0001 |
| Imaging or genotyping procedures | ||||
| MRI or radiograph | 4559 (38.2) | 1301 (46.3) | 3258 (35.7) | < 0.0001 |
| Radiograph | 3946 (33.0) | 1093 (38.9) | 2853 (31.2) | < 0.0001 |
| MRI | 1840 (15.4) | 635 (22.6) | 1205 (13.2) | < 0.0001 |
| HLA-B27 testing | 1708 (14.3) | 379 (13.5) | 1329 (14.6) | 0.1550 |
Values are n (%) unless otherwise specified. AS: ankylosing spondylitis; RA: rheumatoid arthritis; PsA: psoriatic arthritis; IBD: inflammatory bowel disease; MRI: magnetic resonance imaging.